Q-omics provides the consensus-scored WFDC6 profile across patient tissues and cancer cell-line models. WFDC6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, WFDC6 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, WFDC6 RNA expression shows 9,834 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, LUAD, and TGCT as cancer lineages where WFDC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC6 survival associations across molecular data types. WFDC6 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC6 RNA expression–survival associations across cancer types. High WFDC6 expression shows unfavorable associations in KIRC, THCA and LIHC, but favorable associations in BLCA, UCEC and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for WFDC6 RNA expression.
This table summarizes WFDC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC6 shows lower tumor expression in LUAD, THCA, LUSC and HNSC and higher tumor expression in BRCA. The LUAD box plot shows higher WFDC6 RNA expression in normal versus tumor tissue (log2 FC = −1.111, t-test p < 0.001).
This table shows molecular features associated with WFDC6 in patient tissues and cancer cell lines. In patient samples, WFDC6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and STOMACH.
